A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin), in Healthy Children and Adolescents 4 to 17 Years of Age.

Trial Profile

A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin), in Healthy Children and Adolescents 4 to 17 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2015

At a glance

  • Drugs Influenza vaccine (Optaflu) (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 28 Nov 2015 Results published in the Vaccine
    • 28 Apr 2015 Safety findings presented at the 2015 Annual Meeting of the Pediatric Academic Societies.
    • 28 Apr 2015 Pooled analysis safety and tolerability results presented at the 2015 Annual Meeting of the Pediatric Academic Societies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top